Dr ZHEYING ZHU's Outputs (6)

Gastroretentive technologies in tandem with controlled-release strategies: A potent answer to oral drug bioavailability and patient compliance implications (2021)
Journal Article
Vrettos, N. N., Roberts, C. J., & Zhu, Z. (2021). Gastroretentive technologies in tandem with controlled-release strategies: A potent answer to oral drug bioavailability and patient compliance implications. Pharmaceutics, 13(10), 1-36. https://doi.org/10.3390/pharmaceutics13101591

There have been many efforts to improve oral drug bioavailability and therapeutic efficacy and patient compliance. A variety of controlled-release oral delivery systems have been developed to meet these needs. Gastroretentive drug delivery technologi... Read More about Gastroretentive technologies in tandem with controlled-release strategies: A potent answer to oral drug bioavailability and patient compliance implications.

In vivo Evaluation of a Newly Synthesized Acetylcholinesterase Inhibitor in a Transgenic Drosophila Model of Alzheimer’s Disease (2021)
Journal Article
Uras, G., Manca, A., Zhang, P., Markus, Z., Mack, N., Allen, S., Bo, M., Xu, S., Xu, J., Georgiou, M., & Zhu, Z. (2021). In vivo Evaluation of a Newly Synthesized Acetylcholinesterase Inhibitor in a Transgenic Drosophila Model of Alzheimer’s Disease. Frontiers in Neuroscience, 15, Article 691222. https://doi.org/10.3389/fnins.2021.691222

Alzheimer’s disease is a neurodegenerative disease characterized by disrupted memory, learning functions, reduced life expectancy, and locomotor dysfunction, as a result of the accumulation and aggregation of amyloid peptides that cause neuronal dama... Read More about In vivo Evaluation of a Newly Synthesized Acetylcholinesterase Inhibitor in a Transgenic Drosophila Model of Alzheimer’s Disease.

Magnesium isoglycyrrhizinate reduces hepatic lipotoxicity through regulating metabolic abnormalities (2021)
Journal Article
Lu, L., Hao, K., Hong, Y., Liu, J., Zhu, J., Jiang, W., Zhu, Z., Wang, G., & Peng, Y. (2021). Magnesium isoglycyrrhizinate reduces hepatic lipotoxicity through regulating metabolic abnormalities. International Journal of Molecular Sciences, 22(11), Article 5884. https://doi.org/10.3390/ijms22115884

The excessive accumulation of lipids in hepatocytes induces a type of cytotoxicity called hepatic lipotoxicity, which is a fundamental contributor to liver metabolic diseases (such as NAFLD). Magnesium isoglycyrrhizinate (MGIG), a magnesium salt of t... Read More about Magnesium isoglycyrrhizinate reduces hepatic lipotoxicity through regulating metabolic abnormalities.

Discovery of Novel Tacrine–Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease (2021)
Journal Article
Yao, H., Uras, G., Zhang, P., Xu, S., Yin, Y., Liu, J., Qin, S., Li, X., Allen, S., Bai, R., Gong, Q., Zhang, H., Zhu, Z., & Xu, J. (2021). Discovery of Novel Tacrine–Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease. Journal of Medicinal Chemistry, 64(11), 7483-7506. https://doi.org/10.1021/acs.jmedchem.1c00160

Based on a multitarget strategy, a series of novel tacrine–pyrimidone hybrids were identified for the potential treatment of Alzheimer’s disease (AD). Biological evaluation results demonstrated that these hybrids exhibited significant inhibitory acti... Read More about Discovery of Novel Tacrine–Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease.

Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities (2021)
Journal Article
Zhu, H., Li, W., Shuai, W., Liu, Y., Yang, L., Tan, Y., Zheng, T., Yao, H., Xu, J., Zhu, Z., Yang, D.-H., Chen, Z.-S., & Xu, S. (2021). Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. European Journal of Medicinal Chemistry, 216, Article 113316. https://doi.org/10.1016/j.ejmech.2021.113316

A series of novel N-benzylbenzamide derivatives were designed and synthesized as tubulin polymerization inhibitors. Among fifty-one target compounds, compound 20b exhibited significant antiproliferative activities with IC50 values ranging from 12 to... Read More about Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities.

In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207 (2021)
Journal Article
Vrettos, N.-N., Wang, P., Zhou, Y., Roberts, C. J., Xu, J., Yao, H., & Zhu, Z. (2021). In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207. Pharmaceutical Development and Technology, 26(3), 349-361. https://doi.org/10.1080/10837450.2021.1872087

Hypertension is one of the most common chronic cardiovascular disorders. Sustained-release formulations are developed to maintain drug therapeutic levels throughout the treatment of hypertension, to promote patient compliance and improve patient outc... Read More about In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207.